Pharmaceutical group enjoys "transformational year"

PHARMACEUTICAL group Clinigen has ended a “transformational year” with exit velocity to position it as a global leader in its field.

Clinigen’s acquisition of Idis and Link Healthcare has boosted its status in the management and supply of unlicensed and clinical trial medicines.

It said revenues will be up 87% and gross profit up 90% when it publishes its full-year figures in September, driven by the acquisitions and organic growth.

“We had a strong second half performance, completing a transformational year, said Peter George, chief executive of Clinigen Group.

 

“We are entering the new financial year in an excellent position, having delivered on our key strategic objectives. 

“Our priorities now are to capitalise on our market leader positions, drive organic growth and continue to progress the revitalisation of our products.”

The business, headquartered in Burton-upon-Trent, is valued at around £700m.